Robert Leipold

Learn More
PURPOSE To assess the cost-effectiveness of apixaban versus rivaroxaban, low-molecular-weight heparin (LMWH)/dabigatran, and LMWH/vitamin K antagonist (VKA) for the initial treatment and prevention of recurrent thromboembolic events in patients with venous thromboembolism (VTE). METHODS A Markov model was developed to evaluate the pharmacoeconomic effect(More)
BACKGROUND The economic burden of treating end-stage renal disease (ESRD) continues to grow. As one response, effective January 1, 2011, Medicare implemented a bundled prospective payment system (PPS, including injectable drugs) for dialysis patients. This study investigated the 5-year budget impact on Medicare under the new PPS of changes in the(More)
compare the effectiveness with CAS and CEA in 677 patients with symptomatic carotid artery stenosis in korean clinical practice. Methods: From January 1 2008 to December 31 2011, retrospective cohort study was conducted in 677 symptomatic carotid stenosis patients with more than 50% stenosis) (CAS= 346, CEA= 331) in the Korean hospitals (Asan medical(More)
BACKGROUND Prior analyses beyond clinical trials are yet to evaluate the projected lifetime benefit of apixaban treatment compared to low-molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) for treatment of venous thromboembolism (VTE) and prevention of recurrences. The objective of this study is to assess the cost-effectiveness of initial plus(More)
Background Patients with homozygous familial hypercholesterolemia are at high risk of cardiovascular disease due to high low-density lipoprotein (LDL)-cholesterol levels. Cardiovascular disease outcome studies are impossible to conduct, due to the rarity of homozygous familial hypercholesterolemia. We modelled the potential efficacy of lomitapide, a(More)
  • 1